[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-417727-105":59,"doc-detail-417727-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-comparison-of-toripalimab-versus-pembrolizumab-in-neoadjuvant-breast-cancer-impact-of-chemotherapy-regimen-and-sequence-on-pathologic-complete-response","Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer - impact of chemotherapy regimen and sequence on pathologic complete response","","Real-world evidence compares the domestically developed PD-1 inhibitor toripalimab with pembrolizumab as neoadjuvant therapy for breast cancer, focusing on how treatment cycles, platinum-based chemotherapy, and chemoimmunotherapy sequencing affect pathologic complete response (pCR). In a retrospective cohort of 114 patients, primary endpoints included total pCR while breast pCR and residual cancer burden (RCB) served as secondary outcomes. Overall efficacy showed no significant difference between the two PD-1 inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-comparison-of-toripalimab-versus-pembrolizumab-in-neoadjuvant-breast-cancer-impact-of-chemotherapy-regimen-and-sequence-on-pathologic-complete-response/417727/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-comparison-of-toripalimab-versus-pembrolizumab-in-neoadjuvant-breast-cancer-impact-of-chemotherapy-regimen-and-sequence-on-pathologic-complete-response/417727.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary endpoint used in this study?","Question",{"text":112,"@type":113},"The primary endpoint is total pathologic complete response (tpCR), defined as ypT0/is and ypN0.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Does completing 8 immunotherapy cycles improve outcomes?",{"text":117,"@type":113},"No significant differences were observed in tpCR or RCB-0 rates between patients who completed versus did not complete 8 immunotherapy cycles.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factor significantly affected pCR, chemotherapy regimen or sequence?",{"text":121,"@type":113},"Chemotherapy sequence significantly affected pCR, with the TCb-EC regimen achieving the highest tpCR rate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},417727,1790764106,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Original Research PUBLISHED 19 December 2025 DOI 10.3389/fonc.2025.1699963  \nOPEN ACCESS  \nEDITED BY  \nMohamed Essameldin Abdelgawad,  \nEgypt Center for Research and Regenerative Medicine, Egypt  \nREVIEWED BY  \nMona S. Abdellateif, Cairo University, Egypt Hatem El-mezayen, Helwan University, Egypt  \n*CORRESPONDENCE  \nZhe Wang  \n[wangzhe9263@163.com](wangzhe9263@163.com)[ ](wangzhe9263@163.com)Rui Ling  \n [lingrui0105@163.com](lingrui0105@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 03 October 2025  \nREVISED 14 November 2025  \nACCEPTED 29 November 2025  \nPUBLISHED 19 December 2025  \nCITATION  \nZhang Y, Zhang B, Chen X, Zhang X, Liu C, Wang Z and Ling R (2025) Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response.  \nFront. Oncol. 15:1699963 .  \ndoi: 10.3389/fonc.2025.1699963  \nCOPYRIGHT  \n© 2025 Zhang, Zhang, Chen, Zhang, Liu, Wang and Ling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEfficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer: impact of chemotherapy regimen and sequence on pathologic complete response  \nYunjiao Zhang1†, Bo Zhang2†, Xi Chen 1†, Xue Zhang 1, Chutuo Liu 1, Zhe Wang 1* and Rui Ling 1*  \n1 Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China, 2 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China  \nObjective: This real-world study aimed to compare the efficacy and safety of the domestically developed PD-1 inhibitor toripalimab with pembrolizumab in the neoadjuvant treatment of breast cancer, and to further investigate the impact of treatment cycles, platinum-based chemotherapy, and chemotherapy sequencing on pathologic complete response (pCR) .  \nMethods: This retrospective study included 114 breast cancer patients who received neoadjuvant therapy with either toripalimab or pembrolizumab at the First Affiliated Hospital of Air Force Medical University between January 2021 and January 2025 . Participants were stratified into groups based on: (1) immunotherapy cycles (completed 8 cycles vs. incomplete); (2) chemotherapy regimen (platinum vs. non-platinum); (3) chemotherapy sequence (EC-T, ECTCb, T-EC, TCb-EC, or other); and (4) PD-1 inhibitor type (toripalimab vs. pembrolizumab) . The primary endpoint was total pCR (tpCR; ypT0/is ypN0) . Secondary endpoints included breast pCR (bpCR) and residual cancer burden (RCB) . Statistical analyses incorporated Chi-square tests and Fisher’s exact tests for group comparisons. Baseline characteristics were compared across groups to assess the potential for confounding.  \nResults: No significant differences were observed in tpCR (56 .7% vs. 46. 8%; P=0 . 297) or RCB-0 rates (56 . 7% vs . 44. 7%; P=0 . 524) between patients completing versus not completing 8 immunotherapy cycles. The tpCR rate did not differ significantly between platinum-based and non-platinum-based regimens (53 . 6% vs. 51.7%, P=0 . 843) . Chemotherapy sequence significantly affected efficacy: the TCb-EC group achieved the highest tpCR rate (79.2%), significantly outperforming EC-T (56 . 4%) and other regimens (27 . 3%) . Toripalimab and pembrolizumab showed no significant difference in tpCR rate (56 . 8% vs. 50. 0%, P=0 .777) or RCB-0 rate (56 . 8% vs. 48. 6%, P=0 . 903) . Conclusion: Toripalimab demonstrated non-inferior efficacy compared topembrolizumab in the neoadjuvant treatment of breas","cbCaiv4VNwbbW6Ak","https://ap.wps.com/l/cbCaiv4VNwbbW6Ak","pdf",891035,11,"English","# Introduction\n## Neoadjuvant chemotherapy and pCR\n## PD-1/PD-L1 immunotherapy and clinical rationale\n# Methods\n## Study design and patient stratification\n## Endpoints and statistical analysis\n# Results\n## Immunotherapy cycle completion and outcomes\n## Platinum regimen and pCR/RCB\n## Chemotherapy sequence and efficacy\n## Comparison between toripalimab and pembrolizumab\n# Conclusion","[{\"question\":\"What is the primary endpoint used in this study?\",\"answer\":\"The primary endpoint is total pathologic complete response (tpCR), defined as ypT0/is and ypN0.\"},{\"question\":\"Does completing 8 immunotherapy cycles improve outcomes?\",\"answer\":\"No significant differences were observed in tpCR or RCB-0 rates between patients who completed versus did not complete 8 immunotherapy cycles.\"},{\"question\":\"Which factor significantly affected pCR, chemotherapy regimen or sequence?\",\"answer\":\"Chemotherapy sequence significantly affected pCR, with the TCb-EC regimen achieving the highest tpCR rate.\"}]","Efficacy comparison of toripalimab versus pembrolizumab in neoadjuvant treatment of breast cancer - impact of chemotherapy regimen and sequence on pathologic complete response | PDF",1790610249,28]